{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:50:59Z","timestamp":1770745859868,"version":"3.49.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,18]]},"abstract":"<jats:p>Sepsis caused by extensively drug-resistant (XDR) pathogens is characterized by high mortality rates. Polyspecific intravenous immunoglobulin (IVIG) has been used as an adjunctive therapy in sepsis for a long time, but it is not routinely recommended due inconclusive results. This retrospective study investigates the effect of IVIG therapy on 30-day mortality in 50 patients with sepsis caused by XDR pathogens, according to Sepsis-3 criteria. Fifty patients were included, with 28 receiving IVIG alongside standard treatment. Mortality was 74%, with no significant difference in 30-day mortality (71.4% for IVIG-treated vs 77.3% for non-IVIG-treated, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.886) or intensive care unit (ICU) stay duration (median of 9.0 days for both groups, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.883) between the groups. The study concludes that adding polyspecific IVIG to conventional sepsis treatment does not reduce 30-day mortality or ICU stay in XDR pathogen-induced sepsis.<\/jats:p>","DOI":"10.1097\/md.0000000000042190","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T11:01:28Z","timestamp":1746529288000},"page":"e42190","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes of patients with sepsis due extensively drug-resistant bacterial infections with and without polyspecific intravenous immunoglobulin therapy: A retrospective study"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9782-6807","authenticated-orcid":false,"given":"Caner","family":"Acar","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Ege University, \u0130zmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukriye Miray Kilincer","family":"Bozgul","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Ege University, \u0130zmir, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haydar Cagatay","family":"Yuksel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Ege University, \u0130zmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devrim","family":"Bozkurt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Ege University, \u0130zmir, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250904","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"R2-20250904","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"key":"R3-20250904","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-020-02950-2","article-title":"Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019\u2013results from a systematic review and meta-analysis.","volume":"24","author":"Bauer","year":"2020","journal-title":"Crit Care"},{"key":"R4-20250904","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R5-20250904","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/CCM.0000000000002074","article-title":"Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome.","volume":"45","author":"Mira","year":"2017","journal-title":"Crit Care Med"},{"key":"R6-20250904","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jhin.2019.06.005","article-title":"Incremental clinical and economic burden of suspected respiratory infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States.","volume":"103","author":"Tabak","year":"2019","journal-title":"J Hosp Infect"},{"key":"R7-20250904","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges.","volume":"30","author":"Wong","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"R8-20250904","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/CCM.0000000000000125","article-title":"Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients.","volume":"42","author":"Lee","year":"2014","journal-title":"Crit Care Med"},{"key":"R9-20250904","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14787210.2017.1251840","article-title":"Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections.","volume":"15","author":"Bassetti","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R10-20250904","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/jac\/dkaa478","article-title":"Impact of antibiotic timing on mortality from Gram-negative bacteraemia in an English district general hospital: the importance of getting it right every time.","volume":"76","author":"Baltas","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"R11-20250904","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s13054-014-0596-8","article-title":"Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study.","volume":"18","author":"Zilberberg","year":"2014","journal-title":"Crit Care"},{"key":"R12-20250904","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s15010-014-0706-1","article-title":"In vitro and in vivo activity of hyperimmune globulin preparations against multiresistant nosocomial pathogens.","volume":"43","author":"Rossmann","year":"2015","journal-title":"Infection"},{"key":"R13-20250904","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"R14-20250904","first-page":"1","article-title":"Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options.","volume":"9","author":"Liu","year":"2022","journal-title":"Mil Med Res"},{"key":"R15-20250904","doi-asserted-by":"crossref","first-page":"ofy150","DOI":"10.1093\/ofid\/ofy150","article-title":"Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to enterobacteriaceae: results of a systematic literature review and meta-analysis.","volume":"5","author":"Martin","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"R16-20250904","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1378\/chest.09-0087","article-title":"Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock.","volume":"136","author":"Kumar","year":"2009","journal-title":"Chest"},{"key":"R17-20250904","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial.","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"R18-20250904","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2017.06.022","article-title":"In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii.","volume":"51","author":"Seifert","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"R19-20250904","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2249.2003.02365.x","article-title":"Stimulation of innate immunity by susceptible and multidrug-resistant Pseudomonas aeruginosa: an in vitro and in vivo study.","volume":"135","author":"Giamarellos-Bourboulis","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"R20-20250904","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00134-015-3751-z","article-title":"Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial.","volume":"41","author":"Payen","year":"2015","journal-title":"Intensive Care Med"},{"key":"R21-20250904","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.3390\/ijms21155543","article-title":"Use of intravenous immunoglobulins in sepsis therapy \u2013 a clinical view.","volume":"21","author":"Jarczak","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"R22-20250904","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.2009.04022.x","article-title":"Intravenous immunoglobulins \u2013 understanding properties and mechanisms.","volume":"158","author":"Durandy","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"R23-20250904","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbrc.2015.06.004","article-title":"Intravenous immunoglobulin enhances the killing activity and autophagy of neutrophils isolated from immunocompromised patients against multidrug-resistant bacteria.","volume":"464","author":"Matsuo","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"R24-20250904","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1007\/s42770-023-01153-5","article-title":"In vitro evaluation of human intravenous immunoglobulin in combination with antimicrobials and human serum against multidrug-resistant isolates of Acinetobacter baumannii.","volume":"54","author":"de Lima","year":"2023","journal-title":"Braz J Microbiol"},{"key":"R25-20250904","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.transci.2016.12.017","article-title":"Mechanisms of action of intravenous immunoglobulin.","volume":"56","author":"Chaigne","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"R26-20250904","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/10245332.2018.1538001","article-title":"The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments.","volume":"24","author":"Benbrahim","year":"2019","journal-title":"Hematology"},{"key":"R27-20250904","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13613-018-0466-7","article-title":"Effects of the timing of administration of IgM- and IgA-enriched intravenous polyclonal immunoglobulins on the outcome of septic shock patients.","volume":"8","author":"Berlot","year":"2018","journal-title":"Ann Intensive Care"},{"key":"R28-20250904","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13054-017-1764-4","article-title":"Low-dose immunoglobulin G is not associated with mortality in patients with sepsis and septic shock.","volume":"21","author":"Iizuka","year":"2017","journal-title":"Crit Care"},{"key":"R29-20250904","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cmi.2016.01.021","article-title":"Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins.","volume":"22","author":"Giamarellos-Bourboulis","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"R30-20250904","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1186\/s12967-023-04592-8","article-title":"Efficacy of IVIG therapy for patients with sepsis: a systematic review and meta-analysis.","volume":"21","author":"Pan","year":"2023","journal-title":"J Transl Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:01:39Z","timestamp":1756987299000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":30,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042190","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]}}}